^
    Back
    Association details:
    Biomarker:CD19 positive
    Cancer:Non-Hodgkin’s Lymphoma
    Drug:CTX110 (CD19-targeted CAR-T immunotherapy)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    CRISPR Therap Press Release
    Title:

    CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX110™ for the Treatment of Relapsed or Refractory CD19+ B-cell malignancies

    Published date:
    11/22/2021
    Excerpt:
    CRISPR Therapeutics...today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to CTX110™, its wholly-owned allogeneic CAR-T cell therapy targeting CD19+ B-cell malignancies.
    Trial ID:
    CARBON